Abstract
This study investigated the efficacy and safety of citalopram in the treatment of eating disorders. Eighteen female patients gave their informed consent to enrolment in the trial: twelve with bulimia nervosa, six with anorexia nervosa according to the DSM IV criteria. They received individual systemic psychotherapy and took 20 mg/day citalopram for 8 weeks. At the beginning and end of the trial, their BMI, body fat and lean mass were checked and they completed the Eating Disorder Inventory and Binge Scale. The results showed that citalopram is effective and safe in the treatment of eating disorders: binge eating episodes and mean scores in three EDI subscales (bulimia, ineffectiveness and interoceptive awareness) significantly decreased in the bulimic patients, and mean scores in the EDI body dissatisfaction subscale significantly decreased in the anorexic patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Goldstein D.J., Wilson M.G., Thompson V.L., Potvin J.H., Rampey A.H. Jr.: Long term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br. J. Psychiatry, 166, 660–666, 1995.
Stokes P.E., Holtz A.: Fluoxetine tenth anniversary update: the progress continues. Clin. Ther., 19, 1135–1150, 1997.
Advokat C., Kutlesic V.: Pharmacotherapy of the eating disorders: a commentary. Neurosci. Biobehav. Rev., 19, 59–66, 1995.
Finley P.R.: Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann. Pharmacother., 28, 1359–1369, 1994.
Brambilla F., Draisci A., Peirone A., Brunetta M.: Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa binge eating/purging type. Neuropsychobiology, 32, 64–67, 1995.
Rissanen A., Naukkarinen H., Virkkunen M., Rawlings R.R., Linnoila M.: Fluoxetine normalizes increased cardiac vagal tone in bulimia nervosa. J. Clin. Psychopharmacol., 18, 26–32, 1998.
Fichter M.M., Kruger R, Rief W, Holland R, Dohne J.: Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating specific psychopathology. J. Clin. 1994 Dec. Psychopharmacol., 16, 9–18, 1996.
Fichter M.M., Leibl C., Kruger R., Rief W.: Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry, 30, 85–92, 1997.
Cebollada A., Chinchilla A., Vega M. et al: Psychopharmacological treatment of anorexia nervosa. Eur. Neuropsychopharmacol. 11, 273–278, 1996.
Calandra C., Gulino V.: Individual psychotherapy by a systemic approach in bulimic patients. Minerva Psichiatr., 40, 47–52, 1999.
Garner D.M. et al: Development and validation of a multidimensional Eating Disorder Inventory for anorexia nervosa and bulimia nervosa. Int. J. Eating Disord., 2, 15, 1983.
Hawkins R., Clement P.: Development and costruct validation of a self report measure of binge eating tendencies. Addict. Behav., 5, 219, 1980.
Author information
Authors and Affiliations
Additional information
This study was performed in accordance with the ethical standards laid down in the Declaration of Helsinki.
Rights and permissions
About this article
Cite this article
Calandra, C., Gulino, V., Inserra, L. et al. The use of citalopram in an integrated approach to the treatment of eating disorders: An open study. Eat Weight Disord 4, 207–210 (1999). https://doi.org/10.1007/BF03339739
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03339739